Solésence 10-Q/A Restates Q3 2025: Inventory Cut $3.7M, Equity Down to $13.5M
SLSN sits 42% above its 52-week low of $0.613.
Summary
Solésence's amended Q3 2025 10-Q restates inventory down $3.742 million and equity to $13.485 million, and formally concludes internal controls were not effective at September 30, 2025 due to two material weaknesses.
Key Events · Corporate Governance and Compliance · SLSN
-
Q3 2025 Restated on Inventory Errors
Inventories at September 30, 2025 fall $3.742 million to $15.127 million from $18.869 million as previously reported, while total assets drop to $50.245 million from $53.987 million.
-
Equity Cut to $13.5 Million
Stockholders' equity falls $3.742 million to $13.485 million from $17.227 million, and the accumulated deficit widens to $102.543 million.
-
Controls Concluded Not Effective
Management concluded that disclosure controls and ICFR were not effective at September 30, 2025, superseding the original 10-Q conclusion and citing material weaknesses in inventory costing and in oversight and review of financial reporting and restatement activities.
-
Cash Flow Unchanged by Restatement
Net cash used in operating activities stays at $10.386 million for the nine months and period-end cash at $429,000; the restatement did not affect actual cash receipts or payments.
Analysis · SLSN · Industrial Applications And Services
The credibility question is the story here, not liquidity. This amendment rewrites the September 30, 2025 quarter originally filed November 12, 2025, cutting inventories by $3.742 million and pulling stockholders' equity down to $13.485 million from $17.227 million as first reported. Management also reversed its earlier clean opinion, concluding that disclosure controls and internal control over financial reporting were not effective at September 30, 2025 because of two material weaknesses — inventory costing and oversight of financial reporting and restatement activities. Cash, by contrast, is untouched: net cash used in operations stays at $10.386 million and period-end cash at $429,000, so the restatement is an accounting and credibility problem rather than a liquidity event. Against a $61 million market cap, a $3.7 million equity hit and a second consecutive quarter of 'controls not effective' raise real questions about the reliability of reported margins while the company works through a Nasdaq sub-$1 bid-price notice received September 29, 2026.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLSN was trading at $0.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $61.5M. The 52-week trading range was $0.61 to $3.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.